Novartis Prevails In Bone Drug Trial In NC

Law360, Los Angeles (May 14, 2014, 8:39 PM EDT) -- A North Carolina federal jury found Wednesday that Novartis Pharmaceutical Corp.'s failure to provide an adequate warning regarding the use of its bone drugs Zometa and Aredia didn't proximately cause a user's jaw injury, handing the company another victory in a far-reaching product liability battle over the drugs.

Following a seven-day trial, the jury returned a verdict in favor of Novartis on plaintiff Jimmy Earp's state law failure-to-warn claim. Earp alleged he developed osteonecrosis — also known as "bone death" — of the jaw as a result of using Aredia and Zometa as part of a treatment regimen for his multiple...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!